CTRI/2017/06/008746已完成2/3 期
Role of Nimbadi eye drops in Netrabhishyanda in the special reference to infective conjunctivitis.
试验速览
- 阶段
- 2/3 期
- 状态
- 已完成
- 发起方
- RUBY
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change in scores of symptoms and signs of infective conjunctivitis
研究概览
简要总结
This study has been planned to evaluate the efficacy of Nimbadi eye drops on symptoms and signsof Infective Conjunctivitis (Netrabhishyanda) as compared to Levofloxacin 0.5%ophthalmic solution on 30 patients of infective conjunctivitis. It has been planned to assess the disease condition on clinical basis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 12.00 Year(s) 至 80.00 Year(s)(—)
- 性别
- All
入选标准
- •patients with at least 12 years of age and having clinical diagnosis of infective conjunctivitis at least in one eye.
排除标准
- •Patients with any concomitant disease of eye which could interfere with assessment of infective conjunctivitis (Netrabhishyanda) such as anterior uveitis, scleritis, episcleritis etc.
- •were excluded from the study Patients who develop any complication during the trial will be excluded.
结局指标
主要结局
Change in scores of symptoms and signs of infective conjunctivitis
时间窗: Day 2, Day 5, Day 10
次要结局
- Change in scores of symptoms and signs of infective conjunctivitis(Day 2, Day 5, Day 10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A clinical trial to compare the effects of Ayurvedic Eye Drops with Antibiotic Eye Drops for conjunctivitis.CTRI/2017/06/008746RUBY30
已完成
3 期
Confirmatory Study Nepafenac 0.3%CataractNCT01109173Alcon Research2,120
已完成
3 期
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular HypertensionPrimary Open-angle GlaucomaOcular HypertensionNCT03235232EMS406
尚未招募
1 期
sing exosome to treat severe dry eyesSevere dry eye.Dry eye syndrome of unspecified lacrimal glandH04.129IRCT20170211032503N2Vision health research center30
已完成
3 期
Study of Rebamipide Eye Drops to Treat Dry EyeKeratoconjunctivitis SiccaNCT00201955Otsuka Pharmaceutical Development & Commercialization, Inc.762
